Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.36 |
| ▸ | TACR1 | P25103 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16207758 | 0.82 | KIF11 (0.36) | MEN1MAPTKMT2AMAPK1ALDH1A1 | |
| SCHEMBL30947610 | 0.77 | NOS3 (0.53) | NOS3NOS2MBOAT4ADRB1SLC6A4 | |
| SCHEMBL1843485 | 0.76 | NOS3 (0.52) | NOS3NOS2MBOAT4ADRB1SLC6A4 | |
| SCHEMBL29442871 | 0.76 | NOS3 (0.52) | NOS3NOS2MBOAT4ADRB1SLC6A4 | |
| SCHEMBL2304178 | 0.76 | NOS3 (0.52) | NOS3NOS2MBOAT4ADRB1SLC6A4 | |
| SCHEMBL24442286 | 0.76 | NOS3 (0.52) | NOS3NOS2MBOAT4ADRB1SLC6A4 | |
| SCHEMBL1443247 | 0.76 | NOS3 (0.57) | NOS3NOS2MBOAT4ADRB1SLC6A4 | |
| SCHEMBL29442849 | 0.76 | NOS3 (0.52) | NOS3NOS2MBOAT4ADRB1SLC6A4 | |
| SCHEMBL5260538 | 0.76 | NOS3 (0.52) | NOS3NOS2MBOAT4ADRB1SLC6A4 | |
| SCHEMBL2616106 | 0.76 | NOS3 (0.52) | NOS3NOS2MBOAT4ADRB1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066351-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD (US) | 2025-02-27 | — | — | US | disclosed |
| EP-4460501-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (US) | 2024-11-13 | — | — | EP | disclosed |
| CN-118510777-A | Pyrazolo [1,5-a ] pyridin-2, 3-ylamides as Kv7 channel activators | 拜奥海芬治疗学有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023133256-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (US) | 2023-07-13 | — | — | WO | disclosed |
| WO-2022222911-A1 | PYRIMIDONE COMPOUND AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-10-27 | — | — | WO | disclosed |
| EP-1613299-A2 | COMBINATION PRODUCT FOR CONTROLLING INSECT PESTS | Novartis AG (CH) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004043446-A2 | COMBINATION PRODUCT FOR CONTROLLING INSECT PESTS | NOVARTIS AG (CH) | 2004-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250066351-A1 | PYRAZOLO[1,5-A]PYRIDIN-2,3-YL AMIDES AS KV7 CHANNEL ACTIVATORS | KCNA7, KCNK17, KCNA1 | NOS3 2893/4885NOS2 3513/4885MBOAT4 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.